Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression
Clinical trial NCT05512182 · WITHDRAWN
Trial details
- NCT number
- NCT05512182
- Sponsor
- Yonsei University
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-15
- Primary completion
- 2023-10-30
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.